Hann.Bo
HANN.BO operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, primarily generating revenue through product sales and service offerings.
Business. HANN.BO operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, primarily generating revenue through product sales and service offerings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
HANN.BO operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, primarily generating revenue through product sales and service offerings.
HANN.BO maintains a capital structure with a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.47, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow stands at INR 23.24 million, which is lower than the operating cash flow of INR 196.02 million, indicating some capital expenditure pressure.
Profitability metrics show a return on equity (ROE) of 13.88% and a return on assets (ROA) of 7.26%, both of which are strong indicators of efficient asset and equity utilization. The company's operating income of INR 134.49 million and net income of INR 72.10 million reflect a healthy margin, although the gross profit margin of 85.13% (INR 659.83 million on INR 775.31 million revenue) suggests a competitive cost structure.
Geographically and segment-wise, HANN.BO's revenue concentration is not disclosed in the available data. However, the company's operations are primarily focused on the healthcare facilities and services segment, with no additional segment details provided. The lack of segment-specific revenue breakdown limits the ability to assess diversification or concentration risk.
The company's growth trajectory is supported by a revenue of INR 775.31 million, with no specific growth rate provided. The capital expenditure of INR -121.27 million indicates ongoing investment in infrastructure or expansion. The outlook for the current fiscal year is not explicitly provided, but the company's financial performance suggests a stable growth path.
Risk factors include a medium liquidity risk, as the company's net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified. The company's capital structure and financial leverage are within acceptable ranges, but the negative net cash position could pose challenges in the event of a liquidity crunch.
Recent events and filings are not detailed in the available data, but the company's financial statements and risk assessment suggest a stable operational environment. The absence of recent significant events or regulatory actions indicates a relatively low-profile risk profile.
- HANN.BO demonstrates strong profitability with a ROE of 13.88% and ROA of 7.26%.
- The company's liquidity position is moderate, with a current ratio of 1.47 and a debt-to-equity ratio of 0.71.
- Capital expenditures of INR -121.27 million indicate ongoing investment in infrastructure.
- The company's dilution risk is low, and its liquidity risk is assessed as medium.
- Revenue concentration and segment-specific details are not disclosed, limiting the assessment of diversification risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- HANN.BO Market data — financials · 2026-05-28